Brivanib
As of the edition of 20 October 2026, Brivanib is a small molecule: stopped in 2013; acts on FGFR1, FGFR2 and FGFR3 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Small molecule
- Registered trials
- 15, 2 stopped early
- Disease areas
- Cancer; Digestive system; Pregnancy and women's health; Urinary and reproductive; Bones, joints and muscles; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Brivanib.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| FGFR1 | Fibroblast growth factor receptor 1 | P11362 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FGFR2 | Fibroblast growth factor receptor 2 | P21802 |
| FGFR4 | Fibroblast growth factor receptor 4 | P22455 |
| FGFR3 | Fibroblast growth factor receptor 3 | P22607 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 7 | 0 | 0 |
| Phase 2 | 5 | 3 | 0 | 1 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2000 to now |
| Zai Lab | Lead sponsor of trials | 2017 to now |